Atorvastatin (CI-981) clinical pharmacokinetic study (III) - Effect of food on bioavailability of atorvastatin -

Japanese Pharmacology and Therapeutics

Volumn 26, Issue 8, 1998, Pages 93-103

  Oishi, Shimako ^a   Watanabe, Takashi ^a   Higuchi, Saburo ^a   Minohara, Kazuo ^b   Tsunoo, Michio ^c   Momomura, Shin Ichi ^c   Nakamura, Norihiko ^c   Iwasawa, Kuniaki ^c   Kunimi, Toshihiro ^c   Mabuchi, Yasuo ^c   Kujira, Hiroya ^c  

^a Yamanouchi Pharmaceutical Co Ltd

^b Parke Davis Pharmaceuticals

^c Hosen Clinic

Author keywords

Atorvastatin; Bioavailability; CI 981; Clinical pharmacokinetics; Effect of food; HMG CoA reductase inhibitor; Lipid regulator

Indexed keywords

ATORVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 7344224896     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Baumann KL et al : The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 33 : 2283-2284, 1992
2. CI-981 (Atorvastatin) 14 : 1559-1584, 1998
3. CI-981 (Atorvastatin) 14 : 1585-1600, 1998
4. CI-981 (Atorvastatin) 14 : 1601-1611, 1998
5. CI-981 (Atorvastatin) 14 : 1613-1622, 1998
6. CI-981 (Atorvastatin) 14 : 1623-1628, 1998
7. Japan Cholesterol Lowering Atorvastatin SLudy (J-CLAS) Group : Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 79 : 1248-1252, 1997
8. Nawrocki JW et al ; Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15 : 678-682, 1995
9. Bakker-Arkema RG et al : Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275 : 128-133, 1996
10. Radulovic LL et al : Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 35 : 990-994, 1995
11. Pan HY et al : Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 31 : 291-294, 1993
12. Smith HT et al : Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 6 : 375S-382S, 1993
13. Mauro VF : Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24 : 195-202 1993
14. McMillan K : Considerations in the formulary selection of hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 53 : 2206-2214, 1996
15. Roland M, Tozer TN : Integration with kinetics. Clinical Pharmacokinetics: Concepts and Applications. 2nd ed, p 177-193, Lea and Febiger, 1989